



New Data of Emicizumab Presented at The American Society of Hematology 2017

TOKYO, November 2, 2017 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that oral and poster presentations will be given with regard to emicizumab at [The American Society of Hematology](#) (ASH) 2017 in Atlanta, Georgia, United States. Emicizumab is a bispecific antibody under development for hemophilia A.

Data from additional six-month follow-up of global Phase III studies in hemophilia A with inhibitors to factor VIII, HAVEN 1 study (NCT02622321) and HAVEN 2 study (NCT02795767), will be shown at the conference. The HAVEN 2 will be presented at 7:30 EST on December 9 as part of the official Press Program at ASH. Both studies have been conducted in collaboration with Roche and Genentech, while HAVEN 1 is for adults and adolescents and HAVEN 2 is for children.

In addition, preliminary data from HAVEN 4 study (NCT03020160), a Phase III study with hemophilia A patients with or without inhibitors which examines emicizumab prophylaxis administered subcutaneously once every four weeks, and real-world data from a non-interventional trial in children under 12 years of ages with hemophilia A with inhibitors will be presented.

Major abstracts regarding emicizumab at ASH 2017

Abstract title	Abstract number/Presentation details
Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study	#1071 Poster (session 322) 09 Dec 2017 17:30 – 19:30 EST
HAVEN 2 Updated Analysis: Multicenter, Open-label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors	#85 Oral presentation (session 322) 09 Dec 2017 09:45 EST (09:30 – 11:00 EST)
Emicizumab Subcutaneous Dosing Every 4 Weeks for the Management of Hemophilia A: Preliminary Data from the Pharmacokinetic Run-in Cohort of a Multicenter, Open-label, Phase 3 Study (HAVEN 4)	#86 Oral presentation (session 322) 09 Dec 2017

	10:00 EST (09:30 – 11:00 EST)
Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-interventional Study (NIS) from a Real-World Setting	#1089 Poster (session 322) 09 Dec 2017 17:30 – 19:30 EST